KORU Medical Systems (KRMD) Expected to Post Earnings on Tuesday

KORU Medical Systems (NASDAQ:KRMD) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.0168) per share and revenue of $11.33 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. KORU Medical Systems had a negative net margin of 4.03% and a negative return on equity of 10.63%. The company had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.62 million. On average, analysts expect KORU Medical Systems to post ($0.02) EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

KORU Medical Systems Stock Up 2.3%

KORU Medical Systems stock traded up $0.07 during trading on Tuesday, hitting $3.12. The stock had a trading volume of 25,702 shares, compared to its average volume of 185,310. The stock’s 50 day moving average is $3.13 and its two-hundred day moving average is $4.02. KORU Medical Systems has a 1 year low of $2.86 and a 1 year high of $6.61. The stock has a market cap of $143.30 million, a price-to-earnings ratio of -77.98 and a beta of 0.39.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wall Street Zen upgraded KORU Medical Systems from a “hold” rating to a “buy” rating in a research note on Saturday, September 26th. Zacks Research cut KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Friday. Craig Hallum reiterated a “buy” rating and set a $6.00 target price on shares of KORU Medical Systems in a research report on Thursday, August 6th. Finally, Weiss Ratings downgraded shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 29th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Insider Transactions at KORU Medical Systems

In related news, insider Adam Kalbermatten acquired 32,000 shares of the stock in a transaction dated Tuesday, September 8th. The shares were purchased at an average price of $3.16 per share, for a total transaction of $101,120.00. Following the transaction, the insider owned 394,017 shares in the company, valued at $1,245,093.72. This represents a 8.84% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 18.50% of the stock is currently owned by insiders.

About KORU Medical Systems

KORU Medical Systems, Inc develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems.

KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.